Global Meperidine (Demerol) Market Continues To Gain Significant Momentum With Elite Pharmaceuticals Inc. Launching Generic Methadone Hydrochloride 5mg And 10 Mg Tablets
Meperidine is one of many narcotic pain medicines that can be prescribed to relieve muscle spasms, which can come with the recommendation of an arthritis specialist. It acts as an anticonvulsant and is used to alleviate the severe symptoms of myasthenia gravis, which is the result of a lack of muscle strength. It was first developed to treat muscular dystrophy, although it is now being used more widely for muscle and joint pain due to a variety of different causes including carpal tunnel syndrome and tendonitis.
Increasing prevalence of cancer and
other pain-related diseases is expected to drive growth of the global
meperidine (Demerol) market. According to the World Health Organization (WHO),
in 2018, around 9.6 million deaths were reported due to cancer globally, of
which 2.09 million cases were due to lung cancer. Cancer is one of those
diseases that can cause severe chronic pain to the patient, where physicians
prefer pharmacological methods to treat the pain and reduce the suffering. For
patients suffering intractable chronic pain where conventional treatment
methods are ineffective, opioid drug therapy is mainly used, in order to get
relief from continuous pain. Generally, patients prefer opioid drugs such as
meperidine for this treatment. Hence, such factors are expected to drive growth
of the global meperidine (Demerol) market. Furthermore, increasing number of
surgical procedures performed worldwide is expected to propel the global
meperidine (Demerol) market growth in the near future. According to Eurostat,
in 2017, around 1.4 million cesarean sections were performed in the European
Union (EU).
Challenges such as increased
addiction to opioids and the availability of alternative opioid medications are
expected to restrain growth of the global meperidine (Demerol) market. Besides,
side effects such as possible generalized seizures is expected to hinder the
global meperidine (Demerol) market growth in the near future. Among regions,
North America is expected to witness significant growth in the global meperidine
(Demerol) market. This is owing to increasing prevalence of osteoarthritis
across the region. According to the Centers for Disease Control and Prevention
(CDC), in 2018, over 30 million people suffered from osteoarthritis in the U.S.
Moreover, Asia Pacific is expected to register a robust growth rate, owing to
the presence of a massive consumer base in the region.
Key companies involved in the global
meperidine (Demerol) market are Vintage Pharmaceuticals, Inc. Pfizer, Inc.,
Epic Pharma, Inc., Hikma Pharmaceuticals USA Inc., and Epic Pharma, Inc.
For instance, in November 2018, Elite
Pharmaceuticals Inc., a provider of abuse-deterrent opioids, launched generic
methadone hydrochloride 5mg and 10 mg tablets by Glenmark Pharmaceuticals,
Inc., USA.
Comments
Post a Comment